Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalothin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.84 |
| ▸ | GLA | P06280 | 1/20 | 0.84 |
| ▸ | APEX1 | P27695 | 1/20 | 0.84 |
| ▸ | PKM | P14618 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalothin SCHEMBL1624515 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL11039891 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL10974577 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL16072835 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL5791156 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL4319851 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL2990 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL9159686 | 1.00 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL1331925 | 0.99 | MAPT (0.98) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL148784 | 0.99 | MAPT (0.98) | MAPTTDP1NR1I2HPGDCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | MAPT 4723/4885TDP1 1293/4885NR1I2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.